Non-invasive Haemodynamic Assessment in Hypertension

NACompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2016

Study Completion Date

December 31, 2017

Conditions
Arterial Hypertension
Interventions
DRUG

lisinopril

"Angiotensin converting enzyme inhibitor recommended in case of:~1. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2)~2. hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)~3. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)~4. balanced profile"

DRUG

Telmisartan

Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)

DRUG

Nebivolol

"Beta-blocker recommended in case of:~1.hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min)"

DRUG

Indapamide/hydrochlorothiazide

"1. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm)~2. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)"

DRUG

Amlodipine

1/ SVRI \> 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)

DRUG

lisinopril

Drug choice at the discretion of physician (blinded to ICG)

DRUG

Telmisartan

Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)

DRUG

Nebivolol

Drug choice at the discretion of physician (blinded to ICG)

DRUG

Indapamide/hydrochlorothiazide

Drug choice at the discretion of physician (blinded to ICG)

DRUG

Amlodipine

Drug choice at the discretion of physician (blinded to ICG)

Trial Locations (1)

04-141

Military Institute of Medicine, Warsaw

All Listed Sponsors
lead

Military Institute od Medicine National Research Institute

OTHER

NCT01996085 - Non-invasive Haemodynamic Assessment in Hypertension | Biotech Hunter | Biotech Hunter